Veno-occlusive disease (VOD) of the liver in Korean patients following allogeneic bone marrow transplantation (BMT): efficacy of recombinant human tissue plasminogen activator (rt-PA) treatment.
10.3346/jkms.1996.11.2.118
- Author:
Je Hwan LEE
1
;
Kyoo Hyung LEE
;
Jong Soo CHOI
;
Dai Young ZANG
;
Sung Bae KIM
;
Sang We KIM
;
Cheolwon SUH
;
Jung Shin LEE
;
Woo Kun KIM
;
Yung Sang LEE
;
Sang Hee KIM
Author Information
1. Department of Medicine, Asan Medical Center, University of Ulsan, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
rt-PA;
VOD;
BMT
- MeSH:
Adolescent;
Adult;
Bone Marrow Transplantation/*adverse effects;
Drug Therapy, Combination;
Female;
Heparin/therapeutic use;
Hepatic Veno-Occlusive Disease/*drug therapy/etiology/physiopathology/prevention & control;
Human;
Immunosuppressive Agents/*adverse effects;
Male;
Preoperative Care/adverse effects;
Radiotherapy/*adverse effects;
Risk Factors;
Tissue Plasminogen Activator/*therapeutic use;
Treatment Outcome
- From:Journal of Korean Medical Science
1996;11(2):118-126
- CountryRepublic of Korea
- Language:English
-
Abstract:
Veno-occlusive disease (VOD) of the liver is a clinical syndrome characterized by hyperbilirubinemia, painful hepatomegaly, and fluid retention. In the bone marrow transplantation (BMT) setting, VOD is caused by dose-intensive chemotherapy and/or radiotherapy used to prepare patients for transplant. VOD occurs in up to 50% of the patients who undergo BMT and is usually associated with a high mortality rate. Until recently, there was no proven effective medical therapy for this condition once it was clinically apparent. We report here on the frequency and treatment result of VOD with rt-PA in our allogeneic BMT patients. Eight patients (median age 28.5 years) underwent allogeneic BMT from December, 1993 to June, 1995 in Asan Medical Center. Six leukemia patients were prepared for BMT with busulfan and cyclophosphmide, while two aplastic anemia patients received cyclophosphamide and antithymocyte globulin. VOD was defined as having two of the following features before day 20 posttransplant: jaundice (bilirubin > or = 2 mg/dL), tender hepatomegaly and/or right upper quadrant pain, ascites and/or unexplained weight gain (> 2% from baseline). All patients who were diagnosed with VOD received rt-PA (10-20 mg/day) and heparin (10,000 U/day). Three (37.5%) of the eight patients developed VOD that occurred between 6 and 10 days posttransplant. All three patients developed jaundice, weight gain, and tender hepatomegaly. Ascites and renal insufficiency occurred in two patients and pleural effusion in one patient. rt-PA and heparin were begun 6 to 26 days posttransplant and rt-PA was administered for 7 to 14 days. All three patients responded to the therapy; bilirubin levels began to decrease at 4 to 13 days from the start of therapy. They are all alive at day 111, 316, and 548 days posttransplant. None of the patients had significant hemorrhagic complications after rt-PA treatment. Prolonged administration of rt-PA was feasible without bleeding episode and it seems that rt-PA may alter the natural course of VOD.
